Operating

Acquired in-process research and development

AbbVie Acquired in-process research and development increased by 200.0% to $744.00M in Q1 2026 compared to the prior quarter.

Analysis

StatementCash Flow Statement
SectionOperating
First reportedQ1 2025
Last reportedQ1 2026May 8, 2026
Metric ID: operating_research_and_development_asset_acquired_other__65ec84

Historical Data

2 periods
 Q1 '25Q1 '26
Value$248.00M$744.00M
QoQ Change—+200.0%
YoY Change—+200.0%
Range$248.00M – $744.00M
Avg YoY Growth+200.0%
Median YoY Growth+200.0%

Acquired in-process research and development at Other Companies

Eli Lilly logo
Eli LillyLLYView metric
Merck & Co. logo
Merck & Co.MRKView metric
Gilead Sciences logo
Gilead SciencesGILDView metric
Biogen logo
BiogenBIIBView metric

Frequently Asked Questions

What is AbbVie's acquired in-process research and development?
AbbVie (ABBV) reported acquired in-process research and development of $744.00M in Q1 2026.